2017 Archived Content
Dinner Short Courses
Tuesday, 21 March, 18:30-21:30
New Directions in Cancer Immunotherapy
CAR T and TCR Manufacturing Challenges to Anticipate and Overcome
Roy D. Baynes, M.D., Ph.D.
Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp & Dohme
Robert Hawkins, Ph.D.
Professor, Cancer Sciences, Cellular Therapeutics, University of Manchester
David Feltquate, M.D., Ph.D.
Vice President, Oncology Development, Bristol-Myers Squibb
Dario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich
Andrew Sewell, Ph.D.
Professor, Institute of Infection & Immunity, Cardiff University School of Medicine
Robert W. Wilkinson, Ph.D.
Director, Oncology Research, MedImmune Ltd.
About the Event
Following the success of our inaugural Cancer Biotherapeutics conference in London, we are pleased to announce the Immuno-Oncology Summit Europe 2017, to be held 20-24 March in the heart of London’s Canary Wharf Business District.
With an expanded three-track program, attendees can now experience a full week of cutting-edge science and discussion. The first track on Novel Approaches for Cancer focuses on advances in T-cell technology including next-generation CAR Ts, TCRs, and TILs. In addition it covers bispecifics: for T and NK cell engagement; in the clinic; and modelling for optimal affinity. The track also presents genetic engineering technologies for T cells, preclinical models, and production strategies, and focuses on specificity, off-target tox, and safety. The second track on Immunomodulatory Approaches will present advances with checkpoint inhibitors, agonistic receptor engagement, NK and macrophage activation, Fc-engineering technologies, and cytokine-based therapies, and address the challenge of tumours unresponsive to checkpoint blockade. It includes a keynote session on current understanding of the role of the immune system in cancer. Combination Immunotherapy will review the strategies and clinical trials for designing rational combination immunotherapies, provide case studies of immune modulator combinations, as well as combinations of checkpoint inhibitors with other modalities, and discuss biomarker- and mechanism-based selection of IO combinations.
“Very stimulatory meeting in an exciting field. Great mix of complementary presentations.”
Kerry Chester, Ph.D., Professor, UCL Cancer Institute
“I believe you managed to collate an excellent mix of speakers spanning the most critical aspects of immune oncology, providing an informal forum for discussions between leaders in the field and new investigators coming from both academia and industry.”
Björn Frendéus, Ph.D., Chief Scientific Officer, BioInvent International AB
“The content of the meeting was highly relevant and up to date.”
Khaterech Ahmadi, Executive Director, MSD-Merck
“The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented.”
Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.
View Additional Attendee Quotes